Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond

This resource center is supported by an educational grant from Gilead Sciences, Inc.

Currently, pembrolizumab and PARP inhibitors are first-line treatment options for patients with PD-L1-positive and germline BRCA mutation-positive triple-negative breast cancer (TNBC), respectively. The HER2-targeting antibody-drug conjugate (ADC) trastuzumab deruxtecan has emerged as a subsequent line therapeutic option for patients with HER2-low TNBC. However, patients with metastatic TNBC (mTNBC) who lack these biomarkers or experience disease progression on biomarker-directed therapy continue to require more effective treatments. TROP2-targeting ADCs, including sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan, are reshaping the treatment landscape to address this critical area of unmet need.

The approval of sacituzumab govitecan has provided a much-needed option for patients with previously treated mTNBC. Promising data from studies combining TROP2-targeting ADCs with immune checkpoint inhibitors have recently emerged, with ADC plus ICI combinations poised to move into the frontline setting for mTNBC treatment. Ongoing research and clinical trials evaluating the efficacy, safety, and sequencing of TROP2-targeting ADCs for mTNBC, both as stand-alone therapies and in combination with ICIs, are crucial to improve outcomes for patients with this aggressive breast cancer subtype. These evolving strategies may soon redefine standards of care, but their complexity and rapid development present challenges for real-world clinical adoption.

This modular BURST CME™ Resource Center features expert faculty delivering concise didactic, panel discussion, and case-based information focused on the integration of TROP2-directed ADCs in metastatic TNBC. Faculty review key data and relevant clinical scenarios and provide their expert perspective on how these data may impact practice in the near future. Through expert guidance and practical application of the latest data, this initiative will help oncology professionals confidently interpret trial results, individualize therapy based on patient and tumor characteristics, manage treatment-related toxicities, and stay current with the evolving role of ADCs in the TNBC treatment landscape.

Click Here to Download Fillable Discussion Guide

Click Here to Download Cancer Insight Summary Slides